Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Cyxone's CEO Tara Heitner will present an introduction to the company on Friday 29 April 2022 at 11.00-11.30 at the digital HC Andersen Capital event. It will be possible to ask questions during the presentation, which will be held in English.
To register, please use the link: https://hcandersencapital643.clickmeeting.com/cyxone-introduction-to-the-share/register
To follow the event: https://www.linkedin.com/events/6923251014040985601/about/
Contact
Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se.For more information, please visit www.cyxone.com